Condition (MeSH)
Polydipsia, Psychogenic
ClinicalTrials.gov lists 9 trials for Polydipsia, Psychogenic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Polydipsia, Psychogenic itself; the rest are tagged with a narrower condition beneath it.
When did Polydipsia, Psychogenic trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polydipsia, Psychogenic trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 6 |
| Observational | 2 |
How many Polydipsia, Psychogenic trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 7 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Polydipsia, Psychogenic? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. | The New England journal of medicine | 2023 | Yes |
| A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. | The Journal of clinical investigation | 2021 | Yes |
| Effect of Arginine on the Hypothalamic-Pituitary-Adrenal Axis in Individuals With and Without Vasopressin Deficiency. | The Journal of clinical endocrinology and metabolism | 2020 | Yes |
| Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'. | Clinical endocrinology | 2017 | No |
| Characteristics and outcomes of patients with profound hyponatraemia due to primary polydipsia. | Clinical endocrinology | 2017 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.